Jefferies Group’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$2.08M Buy
170,142
+91,552
+116% +$1.43M 0.02% 592
2022
Q2
$930K Buy
78,590
+14,932
+23% +$200K 0.01% 819
2022
Q1
$1.21M Buy
63,658
+30,691
+93% +$570K 0.01% 842
2021
Q4
$875K Buy
32,967
+20,338
+161% +$700K 0.01% 1036
2021
Q3
$519K Buy
12,629
+10,237
+428% +$561K ﹤0.01% 1215
2021
Q2
$135K Sell
2,392
-9,615
-80% -$355K ﹤0.01% 1455
2021
Q1
$504K Buy
+12,007
New +$684K ﹤0.01% 1121
2020
Q1
Sell
-28,100
Closed -$832K 2187
2019
Q4
$832K Buy
+28,100
New +$702K 0.01% 1564

Other funds holding EDIT

Jefferies Group's EDIT Position: Q3 2022 in Review

Jefferies Group increased its Editas Medicine (EDIT) stake by 116% in Q3 2022, buying an estimated $1.43M and bringing the position to 170,142 shares worth $2.08M. The position accounts for 0.02% of the portfolio, ranked #592.

Jefferies Group first reported a position in EDIT in Q4 2019 and has held it in 8 quarters since. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Jefferies Group held 170,142 shares of Editas Medicine worth $2.08M as of Q3 2022.
  • Jefferies Group bought 91,552 Editas Medicine shares in Q3 2022, an estimated $1.43M.
  • Editas Medicine made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #592 holding.
  • Jefferies Group first reported a position in Editas Medicine in Q4 2019 and has held it in 8 quarters since.
  • 264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.